BC
BEAM icon

Bridgefront Capital’s Beam Therapeutics BEAM Stock Holding History

Bridgefront Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$811K Buy
+34,018
New +$944K 0.2% 160
2024
Q3 		– Sell
-13,755
Closed -$322K – 537
2024
Q2 		$322K Buy
+13,755
New +$338K 0.13% 272

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Bridgefront Capital's BEAM Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 34,018 shares worth $811K. The stake represents 0.2% of the portfolio and ranks #160 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in BEAM as recently as Q2 2024.

Bridgefront Capital first reported a position in BEAM in Q2 2024 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Bridgefront Capital held 34,018 shares of Beam Therapeutics worth $811K as of Q1 2026.
  • Beam Therapeutics was a new Bridgefront Capital position in Q1 2026.
  • Beam Therapeutics made up 0.2% of Bridgefront Capital's portfolio in Q1 2026, its #160 holding.
  • Bridgefront Capital first reported a position in Beam Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.